SCHEMBL31314092

SCHEMBL31314092

Cn1c(=O)n(COCC[Si](C)(C)C)c2cccc(C3=CCN(C(=O)OC(C)(C)C)CC3)c21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK4 Q16654 1/20 0.50
HTR6 P50406 1/20 0.43
GRM1 Q13255 8/20 0.40
GRM5 P41594 7/20 0.40
NAMPT P43490 1/20 0.40
DGAT2 Q96PD7 1/20 0.39
EED O75530 2/20 0.39
RBBP4 Q09028 2/20 0.39
SUZ12 Q15022 2/20 0.39
EZH2 Q15910 2/20 0.39
SCN9A Q15858 1/20 0.39
CNR1 P21554 1/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29751339 0.84 NPC1 (0.33) PDK4
SCHEMBL24607708 0.84 NPC1 (0.33) PDK4
SCHEMBL31314085 0.84 PARP1 (0.35) PDK4SCN9A
SCHEMBL30289455 0.83 BRD4 (0.43) PDK4GRM1GRM5NAMPTGABRP
SCHEMBL31281722 0.83 PDK4 (0.41) PDK4HTR6GRM1GRM5EED
SCHEMBL31282008 0.83 PDK4 (0.41) PDK4HTR6GRM1GRM5EED
SCHEMBL23536299 0.81 TP53 (0.39)
SCHEMBL29907270 0.80 PDK4 (0.49) PDK4HTR6GRM1GRM5NAMPT
SCHEMBL27144161 0.80 PDK4 (0.49) PDK4HTR6GRM1GRM5NAMPT
SCHEMBL25338150 0.78 BACE1 (0.32) PDK4GRM1GRM5SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620470-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-24 EP disclosed
EP-4615455-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-17 EP disclosed
US-20250059164-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-20 US disclosed
WO-2024264017-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059164-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PDK4 1336/4885HTR6 3032/4885GRM1 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.